Deutsch English Français

Contact

EP2321273

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2321273

EP2321273 - ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 25.09.2015 Database last updated on 28.09.2024
Most recent event Tooltip	25.09.2015	No opposition filed within time limit	published on 28.10.2015 [2015/44]
Applicant(s)	For all designated states Wisconsin Alumni Research Foundation 614 Walnut Street Madison, WI 53705 / US
	[2014/47]
Former [2011/20]	For all designated states Wisconsin Alumni Research Foundation 614 Walnut Street Madison, WI 53705 / US
Inventor(s)	01 / DELUCA, Hector, F. 1809 Hwy. Bb Deerfield WI 53531 / US
	02 / PLUM, Lori, A. 6139 Hwy. H. Arena WI 53503 / US
	03 / CLAGETT-DAME, Margaret 1809 Hwy. Bb Deerfield WI 52531 / US
	[2011/20]
Representative(s)	Duckworth, Timothy John, et al J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	[2013/37]
Former [2011/20]	McCluskie, Gail Wilson, et al J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB
Application number, filing date	09801055.6	24.07.2009
	[2011/20]
	WO2009US51664
Priority number, date	US20080083223P	24.07.2008 Original published format: US 83223 P
	[2011/20]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010011906
	Date:	28.01.2010
	Language:	EN
	[2010/04]
	Type:	A1 Application with search report
	No.:	EP2321273
	Date:	18.05.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 28.01.2010 takes the place of the publication of the European patent application.
	[2011/20]
	Type:	B1 Patent specification
	No.:	EP2321273
	Date:	19.11.2014
	Language:	EN
	[2014/47]
Search report(s)	International search report - published on:	US	28.01.2010
	(Supplementary) European search report - dispatched on:	EP	03.11.2011
Classification	IPC:	C07C401/00	[2011/20]
	CPC:	A61K31/593 (EP,US); A61P3/02 (EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2011/20]
Title	German:	EINMAL WÖCHENTLICHE VERABREICHUNG VON 25-HYDROXY-VITAMIN D3 ZUR BEWAHRUNG EINER ERHÖHTEN STABILEN PHARMAKOKINETISCHEN BLUTKONZENTRATION	[2011/20]
	English:	ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION	[2011/20]
	French:	ADMINISTRATION HEBDOMADAIRE DE 25-HYDROXY VITAMINE D3 POUR MAINTENIR UNE CONCENTRATION SANGUINE À PHARMACOCINÉTIQUE STABLE ÉLEVÉE	[2011/20]
Entry into regional phase	21.02.2011	National basic fee paid
	21.02.2011	Search fee paid
	21.02.2011	Designation fee(s) paid
	21.02.2011	Examination fee paid
Examination procedure	21.02.2011	Examination requested [2011/20]
	22.05.2012	Amendment by applicant (claims and/or description)
	25.10.2012	Despatch of a communication from the examining division (Time limit: M06)
	18.04.2013	Reply to a communication from the examining division
	05.07.2013	Despatch of a communication from the examining division (Time limit: M06)
	07.02.2014	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	10.04.2014	Reply to a communication from the examining division
	06.06.2014	Communication of intention to grant the patent
	07.10.2014	Fee for grant paid
	07.10.2014	Fee for publishing/printing paid
	07.10.2014	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 25.10.2012
Opposition(s)	20.08.2015	No opposition filed within time limit [2015/44]
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	10.04.2014	Request for further processing filed
	10.04.2014	Full payment received (date of receipt of payment) Request granted
	24.04.2014	Decision despatched
Fees paid	Renewal fee
	12.07.2011	Renewal fee patent year 03
	13.07.2012	Renewal fee patent year 04
	10.07.2013	Renewal fee patent year 05
	14.07.2014	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X] - ISH-SHALOM S ET AL, "SU428: Daily, weekly or monthly protocols to reach the desired serum 25-hydroxyvitamin D concentration for the elderly", JOURNAL OF BONE AND MINERAL RESEARCH; 27TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-BONE-AND-MINERAL-RESEARCH, AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH, NEW YORK, NY, US; NASHVILLE, TN, USA, (20050901), vol. 20, no. 9, Suppl. 1, ISSN 0884-0431, page S288, XP009153422 [X] 1-13 * abstract *
	International search	[Y]US2003195171 (DAIFOTIS ANASTASIA G [US], et al);
		[Y]US2005003004 (VEHRING REINHARD [US], et al);
		[Y]US2005101576 (WHITEHOUSE MARTHA J [US], et al);
		[Y] - HEANEY ET AL, "25-Hydroxylation of Vitamin D3: Relation to Circulating Vitamin D3 Under Various Input Conditions", AM J CLIN NUTR, (200806), vol. 87, pages 1738 - 1742, XP008143060
	by applicant	US3607888
		- BLUNT JW ET AL., "25-Hydroxycholecalciferol: A biologically active metabolite of vitamin D3", BIOCHEMISTRY, (1968), vol. 7, pages 3317 - 3322
		- JONES G ET AL., "Current understanding of the molecular actions of vitamin D", PHYSIOL. REV., (1998), vol. 78, pages 1193 - 1231
		- GORHAM ED ET AL., "Optimal vitamin D status for colorectal cancer prevention - A quantitative meta analysis", AM,J. PREV. MED., (2007), vol. 32, no. 3, pages 210 - 216
		- GARLAND CF ET AL., "Vitamin D and prevention of breast cancer: Pooled analysis", J. STEROID BIOCHEM, AND MOL. BIOL., (2007), vol. 103, pages 3 - 5
		- LI HJ ET AL., "A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer", PLOS MEDICINE, (2007), vol. 4, no. 3, pages 562 - 571
		- MUNGER KL ET AL., "Elevated serum 25-hydroxyvitamin D predicts a decreased risk of MS", MULTIPLE SCLEROSIS, (2007), vol. 13, no. 2, page 290
		- LOOKER AC ET AL., "Serum 25-hydroxyvitamin D status of adolescent and adults in two seasonal subpopulations from NHANES III", BONE, (2002), vol. 30, no. 5, pages 771 - 777
		- THACHER TD ET AL., "Nutritional rickets around the world: causes and future directions", ANNALS OF TROPICAL PAEDIATRICS, (2006), vol. 26, no. 1, pages 1 - 16
		- LOOKER AC ET AL., "Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults", J. BONE MIN. RES., (2008), vol. 23, no. 1, pages 143 - 150
		- CHONCHOL M ET AL., "25-Hydroxyvitamin D, insulin resistance, and kidney function in the. Third National Health and Nutrition Examination Survey", KIDNEY INT., (2007), vol. 71, no. 2, pages 134 - 139

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p